Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
 
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
 

Nasoril Nasal Spray - Mometasone Furoate Monohydrate

     
  HOME >> PRODUCTS >> Taj Products >> Nasoril
 Taj  ALL Products View Products According to Category


Nasoril Nasal Spray -
(Mometasone Furoate Monohydrate)

 
     

Nasoril Nasal Spray
Mometasone Furoate Monohydrate

COMPOSITION
Each spray delivers:
Mometasone Furoate Monohydrate USP ……. 50 mcg
Mometasone Furoate Monohydrate equivalent to:
Mometasone Furoate USP…….… 0.05% w/v
Benzalkonium Chloride NF ………0.01% w/v (as preservative)
Phenyl Ethyl Alcohol USP ………. 0.25% v/v (as preservative)

taj Pharma nasoril usedaitel

INDICATIONS
NASORIL is indicated for the treatment of seasonal and perennial allergic rhinitis symptoms in adults and paediatric patients, 2 years of age and older. NASORIL is indicated for the prophylaxis of seasonal allergic rhinitis symptoms in adult and adolescent patients, 12 years and older. NASORIL is also indicated in the treatment of nasal polyps in those aged 18 and above.

Nasoril Nasal Spray - Mometasone Furoate Monohydrate

DOSAGE AND ADMINISTRATION

Seasonal or Perennial Allergic Rhinitis
Adults and adolescents (12 years of age and older): The usual recommended dose is two sprays in each nostril once daily (total dose of 200 mcg). Once symptoms are controlled, dose reduction to one spray in each nostril (total dose of 100 mcg) may be effective for maintenance. If symptoms are inadequately controlled, the dose may be increased to a maximum dose of four sprays in each nostril once daily (total dose of 400 mcg). Dose reduction is recommended following control of symptoms.

NASORIL is indicated for the treatment

Children (between the ages of 6–11 years): The usual recommended dose is one spray in each nostril once daily (total dose of 100 mcg). NASORIL demonstrated a clinically significant onset of action within 12 hours after the first dose in some patients with seasonal allergic rhinitis; however, the full benefit of the treatment may not be achieved in the first 48 hours. Therefore, the patient should continue regular use to achieve full therapeutic benefit.

Nasal Polyposis
The usual recommended starting dose for polyposis is two sprays in each nostril once daily (total daily dose of 200 mcg). If after 5–6 weeks, symptoms are inadequately controlled, the dose may be increased to a dose of two sprays in each nostril twice daily (total daily dose of 400 mcg). The dose should be reduced following control of symptoms. If no improvement in symptoms is seen after 5–6 weeks of twice-daily administration, alternative therapies should be considered.

CONTRAINDICATIONS
Hypersensitivity to any of the ingredients of this preparation contraindicates its use.

PACKAGING INFORMATION
NASORIL NASAL SPRAY
Sales pack contains 100 metered doses

NASORIL Nasal Spray 50 mcg is a metered-dose, manual pump spray unit containing
an aqueous suspension of mometasone furoate
monohydrate equivalent to .......................0.05% w/w
mometasone furoate calculated on the anhydrous basis.
After initial priming (10 actuations), each actuation of the pump delivers a metered spray
containing 100 mg or 100 microliter of suspension
containing mometasone furoate monohydrate equivalent to 50 mcg of mometasone furoate
calculated on the anhydrous basis. Each bottle of NASORIL

NASAL SPRAY 50 MCG PROVIDES 120 SPRAYS.
 

      For more information, please see Full Prescribing Information.
Nasoril Nasal Spray - Mometasone Furoate Monohydrate



Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited,  medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited)
 





 

 

taj Pharma Nasoril Nasal Spray

              
 Print page   Send by mail

For Intranasal Use Only
• Treatment of Nasal Symptoms of Allergic Rhinitis (2.1)
Adults & Adolescents (12 yrs. and older): 2 sprays in each nostril
once daily
Children (2-11 yrs.): 1 spray in each nostril once daily
• Treatment of Nasal Congestion Associated with Seasonal Allergic
Rhinitis (2.2)
Adults & Adolescents (12 yrs. and older): 2 sprays in each nostril
once daily
Children (2-11 yrs.): 1 spray in each nostril once daily
• Prophylaxis of Seasonal Allergic Rhinitis (2.3)
Adults & Adolescents (12 yrs. and older): 2 sprays in each nostril
once daily
• Treatment of Nasal Polyps (2.4)
Adults (18 yrs. and older): 2 sprays in each nostril twice daily. 2 sprays
in each nostril once daily may also be effective in some patients.

 

Treatment of Nasal Polyps
NASORIL Nasal Spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older.
2 DOSAGE AND ADMINISTRATION
Administer NASORIL Nasal Spray 50 mcg by the intranasal route only. Prior to initial use of NASORIL Nasal Spray, 50 mcg, the pump must be
primed by actuating ten times or until a fine spray appears. The pump may be stored unused for up to 1 week without repriming. If unused for more than
1 week, reprime by actuating two times, or until a fine spray appears.
2.1 Treatment of Allergic Rhinitis
Adults and Adolescents 12 Years of Age and Older:
The recommended dose for treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis is 2 sprays (50 mcg of
mometasone furoate in each spray) in each nostril once daily (total daily dose of 200 mcg).
Children 2 to 11 Years of Age:
The recommended dose for treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis is 1 spray (50 mcg of
mometasone furoate in each spray) in each nostril once daily (total daily dose of 100 mcg).
2.2 Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis
Adults and Adolescents 12 Years of Age and Older:
The recommended dose for treatment of nasal congestion associated with seasonal allergic rhinitis is two sprays (50 mcg of mometasone
furoate in each spray) in each nostril once daily (total daily dose of 200 mcg).
Children 2 to 11 Years of Age:
The recommended dose for treatment of nasal congestion associated with seasonal allergic rhinitis is one spray (50 mcg of mometasone furoate
in each spray) in each nostril once daily (total daily dose of 100 mcg).
2.3 Prophylaxis of Seasonal Allergic Rhinitis
Adults and Adolescents 12 Years of Age and Older:
The recommended dose for prophylaxis treatment of nasal symptoms of seasonal allergic rhinitis is 2 sprays (50 mcg of mometasone furoate in
each spray) in each nostril once daily (total daily dose of 200 mcg).
In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with NASORIL Nasal
Spray 50 mcg (200 mcg/day) is recommended 2 to 4 weeks prior to the anticipated start of the pollen season.
2.4 Treatment of Nasal Polyps
Adults 18 Years of Age and Older:
The recommended dose for the treatment of nasal polyps is 2 sprays (50 mcg of mometasone furoate in each spray) in each nostril twice daily
(total daily dose of 400 mcg). A dose of 2 sprays (50 mcg of mometasone furoate in each spray) in each nostril once daily (total daily dose of 200 mcg) is
also effective in some patients
.
 

 

 

 

 

 


 

 

 

 

 


 

 

 

 

 

 

Nasoril® Nasal Spray - Mometasone Furoate Monohydrate Nasal Spray Nasoril side effects Nasoril use Nasoril overdose Nasoril drug Nasoril composition Mometasone Furoate Monohydrate Nasal Spray Manufacturing Pharmaceutical Nasoril® brand contains Nasal Spray Nasoril side effects Nasoril use Nasoril overdose Nasoril drug Nasoril composition Mometasone Furoate Monohydrate Nasal Spray tablets Manufacturing Pharmaceutical Mometasone Furoate Monohydrate manufacturers Nasoril® contains Nasal Spray Manufacturing Mometasone Furoate Monohydrate Nasal Spray Pharmaceutical manufacturers Nasoril side effects Mometasone Furoate Monohydrate Nasoril use Nasoril - Nasal Spray overdose Mometasone Furoate Monohydrate Nasoril drug Nasoril composition Nasal Spray tablets Pharmaceuticals Mometasone Furoate Monohydrate Allopathic Products Manufacturer exporter Supplier india Mometasone Furoate Monohydrate formulations medicines injections insulin Pharmaceutical Mometasone Furoate Monohydrate Product Manufacturing pharmaceuticals custom manufacturing Mometasone Furoate Monohydrate pharmapharmacy Nasoril pharmaceutical drugs pharmaceutical Mometasone Furoate Monohydrate formulations active pharmaceutical ingredients manufacturer pharmaceutical packaging pharmaceutical drugs global pharmaceutical pharmaceutical industry pharmaceutical raw materials pharmaceutical drug manufacturers

 
   
PRODUCTS
 
 
   
   
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
    AFRICA
  ASIA PACIFIC
  EUROPE
  MIDDLE EAST
  THAILAND
  BANGLADESH
  NORTH AMERICA
  SOUTH AMERICA
  RUSSIA
  NEWZELAND
  UNITED KINGDOM



















 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

 www.tajpharma.com

   

 

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement